Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03155620 · OUTCOME

Proportion of Pediatric Patients Whose Advanced Tumors Have Pathway Alterations That Can be Targeted by Select Anti-cancer Drugs

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) · Source last updated 2026-07-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of patients
Interval / dispersion
95% Confidence Interval
Time frame
Up to 2 years from study entry

What was measured

Match rate will be calculated as the percent of eligible patients who have an actionable mutation of interest and are matched to at least one of the subprotocols, and confidence intervals will be constructed using the Wilson score interval method. Patients enrolled on or after Amendment 4 will not be included in this analysis as screening of unselected patients will no longer be conducted.

Analysis population: Patients enrolled after Amendment 4 are not included in this analysis

Groups in this outcome

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

Patients undergo biopsy along with tumor mutational screening of the biopsy material for specific, pre-defined mutations, amplifications, or translocations of interest via tumor sequencing and immunohistochemistry. Patients also undergo collection of blood samples for research purposes.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol1158

Reported measurements

Source class 1
Values in Percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol28Not reported25.530.6Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        25.5
        upper Limit
        30.6
        value
        28
denoms
  1. counts
    1. group Id
      OG000
      value
      1158
    units
    Participants
description
Match rate will be calculated as the percent of eligible patients who have an actionable mutation of interest and are matched to at least one of the subprotocols, and confidence intervals will be constructed using the Wilson score interval method. Patients enrolled on or after Amendment 4 will not be included in this analysis as screening of unselected patients will no longer be conducted.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients undergo biopsy along with tumor mutational screening of the biopsy material for specific, pre-defined mutations, amplifications, or translocations of interest via tumor sequencing and immunohistochemistry. Patients also undergo collection of blood samples for research purposes.
    id
    OG000
    title
    NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
param Type
NUMBER
population Description
Patients enrolled after Amendment 4 are not included in this analysis
reporting Status
POSTED
time Frame
Up to 2 years from study entry
title
Proportion of Pediatric Patients Whose Advanced Tumors Have Pathway Alterations That Can be Targeted by Select Anti-cancer Drugs
type
PRIMARY
unit Of Measure
Percentage of patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice